pharmacology-world-heart-congress-2019-scientifictracks

23 / 32

Page 53
Volume 08 Clinical Pharmacology & Biopharmaceutics
ISSN: 2167-065X
Pharmacology 2019
World Heart Congress 2019
August 19-20, 2019
JOINT EVENT
conferenceseries.com
August 19-20, 2019 Vienna, Austria
&
7th World Heart Congress
24th World Congress on Pharmacology
Drug addiction and treatment compliance
Shirley Taniguchi
USP - São Paulo/Brazil
Statement of the Problem: Neuroleptic-induced extrapyramidal symptoms may hinder adherence to drug
rehabilitation treatment.
Methodology and Theoretical Orientations: This study included 32 patients (mean age of 33.61±1.90) admitted
to a public mental health service in São Paulo (Brazil) due to psychotic symptoms associated with illicit drug use.
Findings: A total of 80.65% of patients were addicted to alcohol alone or alcohol plus cocaine or crack, while
19.35% were addicted to cocaine or crack cocaine. Psychosis (73.08%), aggressive behavior (7.69%), and withdrawal
syndrome (11.10% ), while no effects were registered in the remaining 7.69%. Among cocaine abusers, we observed
hallucinations and delirium (50%), cardiovascular effects (27.76%), and psychomotor agitation (11.12%), while
no effects were observed in the remaining 11.10%. Among crack users, we observed hallucinations and delirium
(50%), and cardiovascular effects (37.50%), while no effects were observed among the remaining 12.50% of patients.
Hallucinations, delirium, psychomotor agitation and psychosis were treated with typical or atypical neuroleptics
(96.88%) or anticonvulsants (3.12%). A total of 80.64% of patients receiving neuroleptics had extrapyramidal
symptoms (acute dystonia akathisia, pharmacological parkinsonism), which were treated with a centrally acting
anticholinergic drug-biperiden (60%) or anticonvulsants/antihistaminics (40%).
Conclusions and significance: Professionals should reconsider the use of typical neuroleptics to treat drug-induced
hallucinations, delirium and psychosis. Their side effects make it difficult for patients to adhere to treatment Thus,
any neuroleptic-induced side effects should always be carefully monitored.
Recent Publications:
MELATTO, I. ; Pequeno, M.D.L. ; SANTOS, A. ; GILBERTO, H. ; MALHEIROS, D. ; ROPERO PELÁEZ, F.J. ;
TANIGUCHI RODRIGUES, G. ;MAGALHÃES, J. ; Taniguchi, S. . Hypothyroidisminpsychiatric patients. EUROPEAN
PSYCHIATRY , v. 41, p. S839-S840, 2017.
BATISTELLA, J. ; HIDA, G. ; MALHEIROS, D. ; RODRIGUES, G. TANIGUCHI ; PELÁEZ, F.J. ROPERO ;
MAGALHÃES, J. ; Taniguchi, S. . Pathologies related to depression in elderly patients. EUROPEAN PSYCHIATRY , v.
41, p. S543, 2017.
TAMARINDO, A. ; VOGEL, C. ; HIDA, G. ; MALHEIROS, D. ; Ropero, J.; Taniguchi, S. . The sedation could consist in
a therapeutic strategy in advanced cancer conditions. European Psychiatry (Paris) , v. 33, p.
S500, 2016.
ROPERO PELÁEZ, FRANCISCO JAVIER ; TANIGUCHI, SHIRLEY . The Gate Theory of Pain Revisited: Modeling
Different Pain Conditions with a Parsimonious Neurocomputational Model. Neural Plasticity , v. 2016, p. 1-14, 2016.
Citações: 1
Taniguchi, S.; MARTINS, R. MASTELARO ; VOGEL, C. ; Ropero, J. ; MASON, R. . Initial Palliative Care Drugs' Side
Effect. European Psychiatry (Paris) , v. 30, p. 1507-1507, 2015.
Taniguchi, S.; MASTELAROMARTINS, R. ; VOGEL, C. ; Ropero, J. ; SALMAN, S. ; ALBUQUERQUE, R. . Neuroleptic
Administration to Oncologic Patients Under Palliative Care. European Psychiatry (Paris) , v. 30, p. 1506, 2015.
Shirley Taniguchi, Clin Pharmacol Biopharm, Volume 08